NASDAQ$TVRD
Tvardi Therapeutics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Cara Therapeutics reported positive topline results from the KOMFORT Phase 2 trial and a net revenue of $23M.
Cara Therapeutics reported a net revenue of $23 million for Q2 2022, driven by profit-sharing from KORSUVA™ injection and a milestone payment from the European Commission approval of Kapruvia®. The KOMFORT Phase 2 trial met its primary endpoint in notalgia paresthetica, and the company anticipates a meeting with the FDA in the second half of 2022.
- Net revenue for 2Q 2022 was $23M, including $8M from KORSUVA™ injection profit-sharing and a $15M milestone payment from Kapruvia® approval.
- KORSUVA injection generated net sales of $16.8 million in the second quarter of 2022.
- KOMFORT Phase 2 trial of oral difelikefalin met the primary endpoint in notalgia paresthetica.
- The company expects to report topline data from the Phase 2 trial in primary biliary cholangitis (PBC) in the second half of 2022.
Headline financials
Revenue & EPS history
Tvardi Therapeutics · Revenue · Quarterly
$23M
Revenue by segment
Tvardi Therapeutics · $8.1M total across 1 segment · Q1 2020
- Collaboration Revenue$8.1M—100.0%
Forward guidance
Cara Therapeutics expects its current cash and cash equivalents will be sufficient to fund its anticipated operating expenses and capital requirements into the first half of 2024.
Tailwinds
- Current cash sufficient to fund operations into the first half of 2024.
- Supportive Phase 1 trials planned.
- Phase 2 trials in PBC and NP are underway.
- Phase 3 trials in CKD and AD are ongoing.
- Potential revenue from KORSUVA injection and Kapruvia commercialization.
Headwinds
- Guidance does not account for potential milestone payments.
- Guidance does not account for potential additional product revenue under collaboration agreements.
- Timing expectations and projected costs for current clinical development plans may change.
- Clinical development plans include trials in PBC, NP, CKD and AD.
- Future product revenue from commercialization of KORSUVA injection or Kapruvia not included in guidance.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+1.4%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+0.6%
Avg return
30 days after
50%
24 / 48 earnings
Positive
+42.3%
Q3 2016
Best reaction
-34.9%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | +5.0% | -2.5% | +11.3% | |
| Q3 2024 | -4.1% | -7.1% | -19.1% | |
| Q2 2024 | -3.9% | -4.1% | -22.2% | |
| Q1 2024 | +1.0% | +4.7% | -5.0% | |
| Q4 2023 | -4.2% | +3.3% | -4.5% | |
| Q3 2023 | +4.3% | +4.8% | +14.3% | |
| Q2 2023 | -6.1% | -1.9% | -31.0% | |
| Q1 2023 | +11.2% | -5.2% | -16.0% | |
| Q4 2022 | -34.9% | -41.1% | -54.2% | |
| Q3 2022 | +3.6% | +20.8% | +35.4% | |
| Q2 2022 | +4.8% | +2.1% | -2.8% | |
| Q1 2022 | +14.7% | +4.5% | +9.8% | |
| Q4 2021 | +11.2% | +3.2% | +17.2% | |
| Q3 2021 | +1.4% | -9.2% | -28.5% | |
| Q2 2021 | +1.6% | +8.4% | +21.6% | |
| Q1 2021 | +3.7% | +5.1% | +10.1% | |
| Q4 2020 | -7.4% | -4.6% | +1.6% | |
| Q3 2020 | +7.7% | +10.5% | +6.4% | |
| Q2 2020 | +2.8% | -3.9% | -8.0% | |
| Q1 2020 | +6.8% | +6.1% | +16.1% | |
| Q4 2019 | -5.2% | -6.4% | -20.6% | |
| Q3 2019 | -4.8% | +3.9% | -20.9% | |
| Q2 2019 | +8.2% | +3.6% | +6.0% | |
| Q1 2019 | -5.1% | -6.7% | -0.4% | |
| Q4 2018 | +13.7% | +7.2% | +13.7% | |
| Q3 2018 | +0.8% | +0.6% | -12.5% | |
| Q2 2018 | +6.0% | +9.6% | +11.3% | |
| Q1 2018 | -3.4% | +1.5% | +30.4% | |
| Q4 2017 | -9.2% | -15.0% | -10.1% | |
| Q3 2017 | +1.2% | +2.2% | +4.9% | |
| Q2 2017 | +22.9% | +8.1% | +4.5% | |
| Q1 2017 | -7.7% | -4.6% | +10.3% | |
| Q4 2016 | -12.3% | -10.9% | +4.1% | |
| Q3 2016 | +42.3% | +58.9% | +61.3% | |
| Q2 2016 | -1.5% | -0.7% | -12.5% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | -3.8% | — | — | |
| Q3 2015 | +11.9% | — | — | |
| Q2 2015 | +4.0% | — | — | |
| Q1 2015 | -1.6% | — | — | |
| Q4 2014 | +10.2% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | -1.8% | — | — | |
| Q2 2013 | -1.8% | — | — | |
| Q1 2013 | -1.7% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | -2.7% | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro